Market cap
$12 Mln
Revenue (TTM)
$133 Mln
P/E Ratio
--
P/B Ratio
0
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -4.60 | -19.13 | -14.78 | -0.26 | 28.11 |
| EBIT | 25.93 | 22.14 | 19.45 | 12.82 | 6.83 |
| Net Profit | 21.47 | 20.75 | 17.29 | 11.47 | 5.57 |
| EPS | -- | -- | -- | -- | -- |
| Book Value | -- | -- | -- | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-21 | Dec-20 |
| EBIT-Margin
| -211.48 | -323.49 | -163.01 | -156.80 | -210.47 |
| Net Margin
| -252.90 | -100.60 | -202.26 | -184.08 | -289.67 |
| Return on equity
| 1,074.88 | 578.23 | -- | 120.90 | 221.75 |
| Return on Capital
| -67.08 | -63.11 | -- | -62.41 | -73.91 |
| Return on Assets
| -53.07 | -53.65 | -29.37 | -49.06 | -57.91 |
| Debt to Equity (x)
| -- | -- | 0.00 | -2.29 | -4.08 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Clovis Oncology (CLVS)
|
--
|
-62.41
|
-73.91
|
-64.91
|
-49.98
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
--
--
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Clovis Oncology (CLVS)
|
--
|
120.90
|
221.75
|
2,881.99
|
-143.16
|
|
Peer Median
|
-40.40
|
--
|
--
|
--
|
--
|
ROA
-29.37
Higher than Peers by 1.61
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Clovis Oncology (CLVS)
|
-29.37
|
-49.06
|
-57.91
|
-52.23
|
-46.04
|
|
Peer Median
|
-30.98
|
--
|
--
|
--
|
--
|
EBIT Margin
-163.01
Lower than Peers by 79.39
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Clovis Oncology (CLVS)
|
-163.01
|
-156.80
|
-210.47
|
-267.18
|
-371.34
|
|
Peer Median
|
-83.62
|
--
|
--
|
--
|
--
|
Net Margin
-202.26
Lower than Peers by 109.59
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Clovis Oncology (CLVS)
|
-202.26
|
-184.08
|
-289.67
|
-284.94
|
-490.78
|
|
Peer Median
|
-92.67
|
--
|
--
|
--
|
--
|
Cash Profit Margin
0.00
Lower than Peers by 0.00
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Clovis Oncology (CLVS)
|
0.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.00
|
--
|
--
|
--
|
--
|
Revenue Growth
-14.78
Lower than Peers by 68.73
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Clovis Oncology (CLVS)
|
-14.78
|
-0.10
|
0.15
|
0.50
|
0.72
|
|
Peer Median
|
53.95
|
--
|
--
|
--
|
--
|
EBIT Growth
19.45
Higher than Peers by 20.25
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Clovis Oncology (CLVS)
|
19.45
|
32.64
|
9.37
|
-7.87
|
-4.32
|
|
Peer Median
|
-0.80
|
--
|
--
|
--
|
--
|
Net Profit Growth
17.29
Higher than Peers by 24.59
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Clovis Oncology (CLVS)
|
17.29
|
28.35
|
7.79
|
-8.81
|
-6.24
|
|
Peer Median
|
-7.30
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Clovis Oncology (CLVS)
|
--
|
-2.29
|
-4.08
|
-3.93
|
3.94
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
-0.01
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Clovis Oncology (CLVS)
|
-0.01
|
-0.04
|
-0.44
|
-0.03
|
0.01
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
0.14
Lower than Peers by 5.67
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Clovis Oncology (CLVS)
|
0.14
|
1.58
|
1.68
|
2.75
|
4.55
|
|
Peer Median
|
5.81
|
--
|
--
|
--
|
--
|
Quick Ratio
0.12
Lower than Peers by 5.57
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Clovis Oncology (CLVS)
|
0.12
|
1.47
|
1.51
|
2.55
|
4.34
|
|
Peer Median
|
5.70
|
--
|
--
|
--
|
--
|
Interest Coverage
-6.11
Lower than Peers by 4.02
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Clovis Oncology (CLVS)
|
-6.11
|
-7.36
|
-14.74
|
-23.09
|
-26.87
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
14.62
Lower than Peers by 4.52
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Clovis Oncology (CLVS)
|
14.62
|
22.64
|
18.60
|
24.24
|
15.90
|
|
Peer Median
|
19.14
|
--
|
--
|
--
|
--
|
Asset Turnover
0.16
Higher than Peers by 0.09
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Clovis Oncology (CLVS)
|
0.16
|
0.28
|
0.26
|
0.19
|
0.12
|
|
Peer Median
|
0.06
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Clovis Oncology (CLVS)
|
--
|
78.90
|
72.44
|
63.62
|
44.75
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Clovis Oncology (CLVS)
|
--
|
208.85
|
253.05
|
282.16
|
451.56
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Clovis Oncology (CLVS)
|
--
|
254.00
|
260.55
|
319.88
|
361.25
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Clovis Oncology (CLVS)
|
--
|
33.76
|
64.94
|
25.91
|
135.07
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Book Value
--
--
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Clovis Oncology (CLVS)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
5.18
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Clovis Oncology (CLVS)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-3.11
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Clovis Oncology (CLVS)
|
-3.11
|
-2.20
|
-1.20
|
-1.04
|
-0.16
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
12
Lower than Peers by 134
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Clovis Oncology (CLVS)
|
12
|
--
|
--
|
--
|
--
|
|
Peer Median
|
146
|
--
|
--
|
--
|
--
|